Pluristem (NASDAQ:PSTI) ended FY18 with an operating loss of $33.7m mostly attributed to R&D expenditure ($22.6m) and as of 30 June 2018 had $30.6m in net cash. The company recently announced its plans to present at several November conferences, including top-line data from its Phase II intermittent claudication (IC) study at the American Heart Association (AHA) Scientific Sessions, as well as an overview of its cell therapy products in clinical development at BioEurope.
A total 172 patients over four arms over 52 weeks
Pluristem’s Phase II clinical study examined 172 patients after 52 weeks for improvement in maximal walking distance (MWD). Each patient received two injections three months apart and were divided into four arms: two injections of 300m cells, two injections of 150m cells, one injection of 300m cells (and one sham) and two sham injections. Patients who received two injections of 300m cells showed a statistically significant improvement in MWD when compared to baseline (p=0.0008).
To read the entire report Please click on the pdf File Below..